Health Professional Radio - Podcast

Positive Results From An Alzheimer's Clinical Trial

Informações:

Sinopsis

Dr. RJ Tesi, CEO of INmune Bio, Inc., a clinical stage immuno-oncology company targeting neuroinflammation to fight brain disease, discusses positive data presented at The Alzheimer’s Association International Conference® 2020 from its XPro1595 Phase 1b Clinical Trial in Alzheimer's disease patients. These data showed the anti-inflammatory effects of XPro1595 on neuroinflammation in the arcuate fasciculus (AF) are impressive and consistent with preclinical data.